A Phase II Study of High-Dose Cetuximab plus Irinotecan in Colorectal Cancer Patients with KRAS Wild-Type Tumors Who Progressed after Standard Dose of Cetuximab plus Irinotecan

Publisher： Karger

E-ISSN： 1423-0232|84|4|210-213

ISSN： 0030-2414

Source： Oncology, Vol.84, Iss.4, 2013-01, pp. : 210-213

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The Role of KRAS Mutations in Predicting the Efficacy of Cetuximab-Plus-Irinotecan Therapy in Irinotecan-Refractory Korean Metastatic Colorectal Cancer Patients

By  

Oncology, Vol. 77, Iss. 3-4, 2009-09 ,pp. : 224-230

Karger

Access to resources Recommend Favorite

Phase II Trial of Cetuximab plus Irinotecan for Oxaliplatin- and Irinotecan-Based Chemotherapy-Refractory Patients with Advanced and/or Metastatic Colorectal Cancer: Evaluation of Efficacy and Safety Based on KRAS Mutation Status (T-CORE0801)

By  

Oncology, Vol. 87, Iss. 1, 2014-06 ,pp. : 7-20

Karger

Access to resources Recommend Favorite

Randomized phase 2 study of pegylated SN‐38 (EZN‐2208) or irinotecan plus cetuximab in patients with advanced colorectal cancer

By  

CANCER, Vol. 119, Iss. 24, 2013-12 ,pp. : 4223-4230

John Wiley & Sons Inc

Access to resources Recommend Favorite

Cetuximab/Irinotecan-Chemotherapy in KRAS Wild-type Pretreated Metastatic Colorectal Cancer: A Pooled Analysis and Review of Literature.

By  

Reviews on Recent Clinical Trials, Vol. 8, Iss. 2, 2013-06 ,pp. : 101-109

Bentham Science Publishers

Access to resources Recommend Favorite

Genetic Polymorphisms of FcγRIIa and FcγRIIIa Are Not Predictive of Clinical Outcomes after Cetuximab plus Irinotecan Chemotherapy in Patients with Metastatic Colorectal Cancer

By  

Oncology, Vol. 82, Iss. 2, 2012-02 ,pp. : 83-89

Karger

Access to resources Recommend Favorite